Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study

In a previous 15-day, Phase II study of patients with de novo or persistent/recurrent Cushing’s disease (core study), treatment with pasireotide 600 μg sc bid reduced urinary free cortisol (UFC) levels in 76 % of patients and normalized UFC in 17 %. The objective of this study was to evaluate the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Boscaro, M., Bertherat, J., Findling, J., Fleseriu, M., Atkinson, A. B., Petersenn, S., Schopohl, J., Snyder, P., Hughes, G., Trovato, A., Hu, K., Maldonado, M., Biller, B. M. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085509/
https://www.ncbi.nlm.nih.gov/pubmed/23943009
http://dx.doi.org/10.1007/s11102-013-0503-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085509/
https://www.ncbi.nlm.nih.gov/pubmed/23943009
http://dx.doi.org/10.1007/s11102-013-0503-3

Ejemplares similares